neurometrix_rgb.jpg
NeuroMetrix Reports that Quell® Technology is to be Evaluated for Neuromyelitis Optica Spectrum Disorder (NMOSD) in a Randomized Controlled Trial
June 15, 2021 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology will be used in a double-blinded, randomized, sham-controlled trial to...
neurometrix_rgb.jpg
NeuroMetrix Announces That Top-Line Results from a Randomized Controlled Trial of Quell® for Treatment of Fibromyalgia to be Presented at Two Upcoming Pain Medicine Conferences
June 09, 2021 08:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that top-line results from a randomized controlled trial of Quell in patients with fibromyalgia will...
neurometrix_rgb.jpg
NeuroMetrix Reports Q1 2021 Financial Results
April 22, 2021 07:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2021. The Company is a leader in...
neurometrix_rgb.jpg
NeuroMetrix, Inc. Announces Date for First Quarter 2021 Financial Results Conference Call
April 15, 2021 13:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 first quarter financial results before the opening of the market on...
neurometrix_rgb.jpg
NeuroMetrix Reports Q4 and Full Year 2020 Financial Results
January 28, 2021 07:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2020. The Company is...
neurometrix_rgb.jpg
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2020 Financial Results Conference Call
January 22, 2021 11:05 ET | NeuroMetrix, Inc.
WOBURN, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2020 fourth quarter and full year financial results before the opening of...
neurometrix_rgb.jpg
NeuroMetrix Reports Q3 2020 Financial Results
October 22, 2020 07:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2020. The Company is a leading...
neurometrix_rgb.jpg
NeuroMetrix, Inc. Announces Date for Third Quarter 2020 Financial Results Conference Call
October 15, 2020 11:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 third quarter financial results before the opening of the market on...
NeuroMetrix Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-the-Counter Pain Relief Device
September 22, 2020 07:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the launch of the Quell Watch App, now available for download from the Apple App store. Quell is a...
neurometrix_rgb.jpg
NeuroMetrix Announces Issuance of New U.S. Patent for Quell® Wearable Technology
September 21, 2020 13:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office will issue on September 22, 2020 U.S. Patent No....